The challenge of interpreting tau PET in AD in DS individuals as well as in other populations remains in the effort of distinguishing actual tau pathology from off-target binding, which underscores the importance of leveraging advanced tracers like [18F]PI-2620 with reduced off-target effects and high affinity to 3/4-repeat tau (Mueller et al., 2020). Here, MAPT is linked to Alzheimer disease.